| Oral Paclitaxel Solution With Immunotherapy and Concurrent SBRT as Neoadjuvant Treatment for Older Adults With NSCLC (NCT07754812) | Shanghai Pulmonary Hospital, Shanghai, China | 2026-06-25 |
| Oral Paclitaxel as Neoadjuvant Therapy in Elderly NSCLC: A Phase II Trial (NCT07599163) | Shanghai Pulmonary Hospital, Shanghai, China | 2026-06-08 |
| Application of Electromagnetic Navigation System in Pulmonary Nodule Localization (NCT07595120) | Shanghai Pulmonary Hospital, Shanghai, China | 2026-05-01 |
| Neoadjuvant SF-SBRT Plus Toripalimab and Chemotherapy in Resectable Stage II-III NSCLC. (NCT07608159) | Shanghai Pulmonary Hospital, Shanghai, China | 2026-05-01 |
| A Clinical Trial on the Outcomes of Comprehensive Enhanced Prophylaxis Management (CEPM) in Chinese Patients With EGFR-Mutated Advanced NSCLC Receiving Amivantamab-Based Regimens (NCT07469488) | Shanghai Pulmonary Hospital, Shanghai, China | 2026-04-30 |
| Nab-Paclitaxel Combined With Local Therapy in Relapsed SCLC (NCT07547332) | Shanghai Pulmonary Hospital, Shanghai, China | 2026-04-06 |
| TEAS for Ipsilateral Shoulder Pain After Video-Assisted Thoracoscopic Lung Surgery (NCT07494591) | Shanghai Pulmonary Hospital, Shanghai, China | 2026-04-01 |
| Combining Furmonertinib With Local Therapy for Inoperable Early-stage Lung Cancer: A Phase II Trial (NCT07517640) | Shanghai Pulmonary Hospital, Shanghai, China | 2026-04-01 |
| Study on the Efficacy and Safety of JSKN016 as Neoadjuvant Therapy in Resectable Stage II-III Non-small Cell Lung Cancer Patients (NCT07493980) | Shanghai Pulmonary Hospital, Shanghai, China | 2026-03-01 |
| Acetohydroxamic Acid Combined With a Short-Course Regimen for MDR-TB (AHA-PLUS) (NCT07393438) | Shanghai Pulmonary Hospital, Shanghai, China | 2026-02-21 |
| A Multi-modal Integrating Imaging and Cell-free DNA Methylation in Lung Cancer Early Detection (CMe-Lung): a Multi-center, Observational Study (NCT07375979) | Shanghai Pulmonary Hospital, Shanghai, China | 2026-02-05 |
| Intrapleural Bupivacaine Analgesia for Postoperative Pain Management After Minimally Invasive Video-Assisted Thoracoscopic Surgery: A Randomized Controlled Trial (NCT07393386) | Shanghai Pulmonary Hospital, Shanghai, China | 2026-02-01 |
| Efficacy of Anti-CTLA-4 Antibody Combined With Sintilimab and Chemotherapy as Neoadjuvant Therapy for Resectable Stage II-III Non-Small Cell Lung Cancer (NCT07410975) | Shanghai Pulmonary Hospital, Shanghai, China | 2026-01-10 |
| IBI363 (PD-1/IL-2α-bias) in Combination With Chemotherapy as Neoadjuvant Therapy in Initially Unresectable Stage III Non-Small Cell Lung Cancer (NCT07408635) | Shanghai Pulmonary Hospital, Shanghai, China | 2026-01-07 |
| Neoadjuvant Sacituzumab Tirumotecan and Limertinib for Potentially Resectable Stage Ⅲ EGFR-mutant Non-small Cell Lung Cancer (NCT07323056) | Shanghai Pulmonary Hospital, Shanghai, China | 2026-01-01 |
| Impact of Sugammadex Versus Neostigmine on Early Postoperative Pulmonary Function (NCT07309393) | Shanghai Pulmonary Hospital, Shanghai, China | 2025-12-30 |
| Synthetic PET From CT Improves Precision Diagnosis and Treatment of Lung Cancer: a Prospective, Observational, Multicenter Study (NCT07243873) | Shanghai Pulmonary Hospital, Shanghai, China | 2025-12-01 |
| Ensartinib After Chemoradiotherapy in Stage III ALK-Mutated NSCLC (NCT07235306) | Shanghai Pulmonary Hospital, Shanghai, China | 2025-12-01 |
| Efficacy and Safety of Early Antifibrotic Therapy for Non-progressive Fibrotic Interstitial Lung Disease (NCT07141810) | Shanghai Pulmonary Hospital, Shanghai, China | 2025-10-01 |
| Segmentectomy vs Lobectomy for 2 - 3cm IASLC Grade 1-2 Lung Adenocarcinoma: A Multi-center RCT (NCT07169903) | Shanghai Pulmonary Hospital, Shanghai, China | 2025-10-01 |
| Bozitinib Combined With Chemotherapy as Radical Treatment for Stage IIA-IIIC MET-Altered Non-Small Cell Lung Cancer (NCT07153770) | Shanghai Pulmonary Hospital, Shanghai, China | 2025-09-20 |
| Thoracic Surgery Intercostal Block Trial With Liposomal vs. Hydrochloride Bupivacaine (NCT07134660) | Shanghai Pulmonary Hospital, Shanghai, China | 2025-09-01 |
| Efficacy and Safety of Huanjingjian Decoction in Women With Premature Ovarian Insufficiency (NCT07020429) | Shanghai Pulmonary Hospital, Shanghai, China | 2025-09-01 |
| Short-Course Regimen With Bedaquiline, Moxifloxacin and Pyrazinamide for Early Bactericidal Activity in Drug-Susceptible Tuberculosis (NCT07129629) | Shanghai Pulmonary Hospital, Shanghai, China | 2025-08-20 |
| A Prospective, Multicenter Clinical Study of Hetrombopag in the Prevention of Thrombocytopenia Caused by Lung Cancer Therapy (NCT07101627) | Shanghai Pulmonary Hospital, Shanghai, China | 2025-08-01 |
| Toripalimab Combined With Chemotherapy as Adjuvant Therapy for Incidental Small Cell Lung Cancer After Radical Resection of Lung Cancer: A Single-Center, Randomized Controlled Clinical Study Protocol Number: LungMate-033 (NCT07097948) | Shanghai Pulmonary Hospital, Shanghai, China | 2025-08-01 |
| Neoadjuvant Sugemalimab + Chemotherapy Followed by Adjuvant Sugemalimab for Patients With Resectable Stage II-IIIA Non-small-cell Lung Cancer Patients (NCT06987734) | Shanghai Pulmonary Hospital, Shanghai, China | 2025-06-19 |
| Predictive Value of PET/CT for Efficacy of Neoadjuvant Immunotherapy in Non-small Cell Lung Cancer (NCT06895941) | Shanghai Pulmonary Hospital, Shanghai, China | 2025-04-30 |
| Comparison of Neoadjuvant Cadonilimab Versus Chemotherapy Combined With PD-1 in the Treatment of Resectable Non-Small Cell Lung Cancer With High PD-L1 Expression: A Single-Center, Randomized, Exploratory Clinical Study (NCT06946836) | Shanghai Pulmonary Hospital, Shanghai, China | 2025-04-21 |
| The C-BRIDGE Study: China Bronchiectasis Research Involving Databases, Genomics, and Endotyping (NCT06900062) | Shanghai Pulmonary Hospital, Shanghai, China | 2025-04-06 |
| The Efficacy and Safety of Ensartinib As Adjuvant Therapy in Stage I ALK-positive NSCLC Patients with High Risk Factors (NCT06772610) | Shanghai Pulmonary Hospital, Shanghai, China | 2025-03-15 |
| Neoadjuvant Chemotherapy Combined With Bispecific Antibody Versus Monoclonal Antibody in Locally Advanced NSCLC (NCT06837948) | Shanghai Pulmonary Hospital, Shanghai, China | 2025-02-18 |
| Post-line Treatment With Teniposide for c-Myc-driven Extensive-stage Small Cell Lung Cancer (NCT06758700) | Shanghai Pulmonary Hospital, Shanghai, China | 2025-02-07 |
| The Effect of Semi-recumbent Position on Hypoxemia After Lung Segment/Lobe Surgery (NCT07060625) | Shanghai Pulmonary Hospital, Shanghai, China | 2024-12-23 |
| An Exploratory Study of Tislelizumab in Combination with Chemotherapy in Immuno-experienced Patients with EGFR/ALK/ROS1-negative Advanced NSCLC in the Second-line Setting (NCT06749886) | Shanghai Pulmonary Hospital, Shanghai, China | 2024-11-19 |
| Vebreltinib for Neoadjuvant in MET-altered Stage IIIA-IIIB (N2) Non-small Cell Lung Cancer (NSCLC) (NCT06644313) | Shanghai Pulmonary Hospital, Shanghai, China | 2024-11-01 |
| Toripalimab and JS004 Combined With Platinum-based Chemotherapy for Relapsed and Extensive-stage Small Cell Lung Cancer (NCT06648200) | Shanghai Pulmonary Hospital, Shanghai, China | 2024-11-01 |
| The Incidence and Risk Factors of Central Nervous System Adverse Events of Lorlatinib in Patients with ALK-positive Advanced Non-small Cell Lung Cancer: a Real-world Study (NCT06652555) | Shanghai Pulmonary Hospital, Shanghai, China | 2024-10-30 |
| Neoadjuvant Sunvozertinib in Stage II-IIIB Non-small Cell Lung Cancer Harboring EGFR Exon 20 Insertion Mutation. (NCT07274761) | Shanghai Pulmonary Hospital, Shanghai, China | 2024-10-17 |
| Long-term Impact of Inhaled Tobramycin for Pseudomonas Aeruginosa Eradication in Bronchiectasis (ERASE II) (NCT06760273) | Shanghai Pulmonary Hospital, Shanghai, China | 2024-10-16 |
| WSI Based DL for Diagnosing the IASLC Grading System of Lung Adenocarcinoma (NCT05925764) | Shanghai Pulmonary Hospital, Shanghai, China | 2024-10-15 |
| The Impact of Communication With Healthcare Providers Via WeChat on Survival Outcomes for Lung Cancer Patietns (NCT06592430) | Shanghai Pulmonary Hospital, Shanghai, China | 2024-10-01 |
| A Clinical Trial of Furmonertinib Combination Therapy As Neoadjuvant Treatment in Resectable EGFR-Mutated NSCLC (NCT06585644) | Shanghai Pulmonary Hospital, Shanghai, China | 2024-10-01 |
| Efficacy of PD-1 Inhibitor Combination Therapy in Non-small Cell Lung Cancer Patients Who Have Not Achieved Major Pathologic Response After Neoadjuvant Immunotherapy: a Multicenter, Phase II Clinical Trial (NCT06620822) | Shanghai Pulmonary Hospital, Shanghai, China | 2024-09-30 |
| A Phase II Study of Ivonescimab Combined with Cadonilimab and Chemotherapy in Extensive-stage Small Cell Lung Cancer (NCT06620796) | Shanghai Pulmonary Hospital, Shanghai, China | 2024-09-30 |
| Induction Therapy With Serplulimab Combined With Chemotherapy for Unresectable Stage III Non-small Cell Lung Cancer (NCT06591910) | Shanghai Pulmonary Hospital, Shanghai, China | 2024-09-20 |
| A Study on the Efficacy of Atezolizumab Combined with Chemotherapy (NCT06780826) | Shanghai Pulmonary Hospital, Shanghai, China | 2024-08-28 |
| A Multicenter Real-World Cohort Study of Adebrelimab Injection in the Treatment of Extensive-Stage Small Cell Lung Cancer (NCT06530797) | Shanghai Pulmonary Hospital, Shanghai, China | 2024-08-01 |
| SHR-A1921 Combined With Adebrelimab in the Treatment of Advanced NSCLC Who Failed the Previous Standard First-line Treatment (NCT06480136) | Shanghai Pulmonary Hospital, Shanghai, China | 2024-07-15 |
| The Clinical Characteristics and Efficacy of Immunotherapy in First-line PD-L1-negative Advanced NSCLC Patients (NCT06496009) | Shanghai Pulmonary Hospital, Shanghai, China | 2024-07-08 |
| Adjuvant Benmelstobart for Stage IB, Grade 3 Invasive Lung Adenocarcinoma (NCT06528847) | Shanghai Pulmonary Hospital, Shanghai, China | 2024-06-05 |
| Phase II Trial of Almonertinib Plus Lastet for EGFR+ Non-small Cell Lung Cancer (NCT06463171) | Shanghai Pulmonary Hospital, Shanghai, China | 2024-06-01 |
| Toripalimab Combined With SBRT for NSCLC (NCT06293690) | Shanghai Pulmonary Hospital, Shanghai, China | 2024-04-15 |
| Neoadjuvant Therapy With Toripalimab and JS004 Combined With Etoposide and Platinum Chemotherapy for Limited-stage Small Cell Lung Cancer : A Phase 2 Trial (NCT06256237) | Shanghai Pulmonary Hospital, Shanghai, China | 2024-04-01 |
| Augmented Reality Navigation Versus Traditional CT Guidance for Preoperative Localization of Pulmonary Nodules (NCT06335563) | Shanghai Pulmonary Hospital, Shanghai, China | 2024-03-14 |
| Neoadjuvant Therapy With Iruplinalkib for Potentially Resectable ALK Positive NSCLC: A Single Arm, Exploratory Trial (NCT06282536) | Shanghai Pulmonary Hospital, Shanghai, China | 2024-03-01 |
| Disitamab Vedotin in Combination with Tislelizumab and Bevacizumab in a Phase II Clinical Study of Locally Advanced or Metastatic Non-small Cell Lung Cancer with HER2 Mutation/amplification/expression (NCT06749860) | Shanghai Pulmonary Hospital, Shanghai, China | 2024-02-02 |
| LM-108 Antibody Combination With Sintilimab for Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NCT06479759) | Shanghai Pulmonary Hospital, Shanghai, China | 2024-01-12 |
| Perioperative Immunotherpay Versus Adjuvant Immunotherapy for Resectable Non-small Cell Lung Cancer (NCT06109402) | Shanghai Pulmonary Hospital, Shanghai, China | 2023-12-20 |
| Exploring the Frontiers of Neoadjuvant Therapy for Lung Cancer: a Prospective Observational Real-world Study (NCT06216782) | Shanghai Pulmonary Hospital, Shanghai, China | 2023-12-16 |
| Patient-derived Tumor-like Cell Cluster Model-based Precision Treatment Strategy on Non-small Cell Lung Cancer (NCT07328945) | Shanghai Pulmonary Hospital, Shanghai, China | 2023-12-01 |
| Robot-assisted vs VATS for Thymoma (NCT06029621) | Shanghai Pulmonary Hospital, Shanghai, China | 2023-11-20 |
| Development and Application of Molecular Evaluation Instrument for Lung Cancer Diagnosis and Treatment (NCT06086587) | Shanghai Pulmonary Hospital, Shanghai, China | 2023-11-07 |
| Neoadjuvant Treatment For Locally Advanced Thymic Cancer (NCT06019468) | Shanghai Pulmonary Hospital, Shanghai, China | 2023-11-04 |
| Exploration on the Value of MRD Based on ctDNA Detection in Predicting Recurrence of Resected Non-small Cell Lung Cancer (NCT05965024) | Shanghai Pulmonary Hospital, Shanghai, China | 2023-10-25 |
| Airway Clearance Technique of Oscillation and Lung Expansion in Bronchiectasis (NCT06393257) | Shanghai Pulmonary Hospital, Shanghai, China | 2023-09-01 |
| The Efficacy and Safety of KN046 Combined With Axitinib (NCT06020352) | Shanghai Pulmonary Hospital, Shanghai, China | 2023-08-25 |
| The Efficiency of Surgery and Radiotherapy After SHR-1316 (Adebrelimab) and Platinum-containing Doublet Induction Therapy for Limited-stage Small Cell Lung Cancer (NCT05496166) | Shanghai Pulmonary Hospital, Shanghai, China | 2023-08-01 |
| Cadonilimab Plus Chemotherapy as First-line Treatment for PD-L1 Negative NSCLC (NCT06424821) | Shanghai Pulmonary Hospital, Shanghai, China | 2023-07-04 |
| Neoadjuvant Therapy With Toripalimab and JS004 Combined With Platinum-based Doublet Chemotherapy for Resectable or Potentially Resectable Stage III Non-small Cell Lung Cancer: A Randomised Controlled, Open-label, Phase 2 Trial (NCT05891080) | Shanghai Pulmonary Hospital, Shanghai, China | 2023-07-01 |
| Application of SERS Technology in Clinical Diagnosis and Prognosis of Lung Cancer Immunotherapy (NCT05885815) | Shanghai Pulmonary Hospital, Shanghai, China | 2023-06-01 |
| Application of SERS Technology Based Intraoperative Navigation System in Lung Cancer (NCT05881057) | Shanghai Pulmonary Hospital, Shanghai, China | 2023-06-01 |
| Narrow Band Imaging (NBI) Under Electronic Bronchoscope in Lung Cancer (NCT04676815) | Shanghai Pulmonary Hospital, Shanghai, China | 2023-06-01 |
| Exploring the Neo-Adjuvant Therapy Effects on Lung Cancer Through Monitoring and Assessment of Tumor Environment (NCT05857800) | Shanghai Pulmonary Hospital, Shanghai, China | 2023-05-25 |
| Deep Learning Signature for Predicting Complete Pathological Response to Neoadjuvant Chemoimmunotherapy in Non-small Cell Lung Cancer (NCT05925751) | Shanghai Pulmonary Hospital, Shanghai, China | 2023-05-01 |
| Deep Learning Signature for Predicting Aggressive Histological Pattern in Resected Non-small Cell Lung Cancer (NCT05925738) | Shanghai Pulmonary Hospital, Shanghai, China | 2023-05-01 |
| Drug Exposure and Minimum Inhibitory Concentration in the Treatment of MAC Lung Disease (NCT05824988) | Shanghai Pulmonary Hospital, Shanghai, China | 2023-04-14 |
| CX3CR1+T Cell Predict Immunotherapy Efficacy (NCT06054152) | Shanghai Pulmonary Hospital, Shanghai, China | 2023-04-10 |
| Induction Therapy With PD-1 Antibody Combined With Platinum-based Doublet Chemotherapy for Locally-advanced Non-small Cell Lung Cancer (NCT05766800) | Shanghai Pulmonary Hospital, Shanghai, China | 2023-03-14 |
| Explore the Optimal Surgical Timing for Lung Surgery and Mediastinal Surgery After COVID-19 Infection (NCT05827328) | Shanghai Pulmonary Hospital, Shanghai, China | 2023-01-29 |
| Deep Learning Signature for Predicting the Novel Grading System of Clinical Stage I Lung Adenocarcinoma (NCT05736991) | Shanghai Pulmonary Hospital, Shanghai, China | 2022-11-01 |
| Neoadjuvant Immunotherapy for Stage III Non-small Cell Lung Cancer (NCT04728724) | Shanghai Pulmonary Hospital, Shanghai, China | 2022-09-10 |
| Screening for Cystic Fibrosis and Cystic Fibrosis Related Disorders in Chinese Adults With Bronchiectasis (NCT05604495) | Shanghai Pulmonary Hospital, Shanghai, China | 2022-09-07 |
| Clinical Study of New Intensive Treatment Regimen for Severe Nontuberculous Mycobacterial Pulmonary Disease (NCT05494957) | Shanghai Pulmonary Hospital, Shanghai, China | 2022-08-05 |
| A Exploratory Study of Vγ2Vδ2 T Lymphocyte-based Immunotherapy for MDR-TB (NCT05493267) | Shanghai Pulmonary Hospital, Shanghai, China | 2022-08-03 |
| Clinical Characteristics of Lung Cancer in China (NCT05423236) | Shanghai Pulmonary Hospital, Shanghai, China | 2022-07-01 |
| Assessment of an Exhaled Breath Test to Detect Bronchiectasis (NCT05293314) | Shanghai Pulmonary Hospital, Shanghai, China | 2022-07-01 |
| Comparison of Single Port and Two Ports Robotic Assisted Thoracic Surgery for Thymectomy (NCT05262582) | Shanghai Pulmonary Hospital, Shanghai, China | 2022-05-10 |
| Neoadjuvant Furmonertinib Plus Bevacizumab or Furmonertinib Monotherapy for Resectable and Potentially Resectable Stage III-IVA EGFR Mutation-Positive Lung Adenocarcinoma (NCT05503667) | Shanghai Pulmonary Hospital, Shanghai, China | 2022-02-01 |
| Deep Learning Signature for Predicting Occult Nodal Metastasis of Clinical N0 Lung Cancer (NCT05425134) | Shanghai Pulmonary Hospital, Shanghai, China | 2022-01-01 |
| Neoadjuvant HS-10296 (Almonertinib) Therapy for Potential Resectable Stage III EGFR Mutation-Positive Non-small Cell Lung Cancer (NCT04685070) | Shanghai Pulmonary Hospital, Shanghai, China | 2021-12-14 |
| Combined Simvastatin and Irinotecan in Treating ES-SCLC Patients Relapsed From 1st Chemotherapy (NCT04985201) | Shanghai Pulmonary Hospital, Shanghai, China | 2021-11-01 |
| Combined Simvastatin and Albumin Paclitaxel in Treating ES-SCLC Patients Relapsed From 1st Chemotherapy (NCT04698941) | Shanghai Pulmonary Hospital, Shanghai, China | 2021-07-25 |
| Efficacy and Safety of Sitafloxacin in the Treatment of Acute Exacerbation of Bronchiectasis in Adults (NCT05313750) | Shanghai Pulmonary Hospital, Shanghai, China | 2021-06-30 |
| Rapid and Accurate Detection of Major Mycobacterium Species in Pulmonary Infection Based on GenSeizer Platform (NCT04345939) | Shanghai Pulmonary Hospital, Shanghai, China | 2021-06-28 |
| Pilot Study of PD-1inhibitor (Tislelizumab) Plus Chemotherapy as Neoadjuvant Therapy for Limited-Stage Small-Cell Lung Cancer (NCT04542369) | Shanghai Pulmonary Hospital, Shanghai, China | 2021-05-01 |
| a Study of SHR1210 in Combination With Paclitaxel-albumin and Carboplatin in Extensive Stage Small Cell Lung Cancer (NCT04790539) | Shanghai Pulmonary Hospital, Shanghai, China | 2021-04-01 |
| A Study of Ultrashort PRS Regimen V in the Treatment of MDR-TB (NCT05278988) | Shanghai Pulmonary Hospital, Shanghai, China | 2021-04-01 |
| Adjuvant Toripalimab Plus Chemotherapy for EGFR/ALK Mutation Negative Stage II-IIIB(N2) NSCLC (LungMate-008) (NCT04772287) | Shanghai Pulmonary Hospital, Shanghai, China | 2021-03-31 |
| Efficiency and Safety of Microwave Ablation Plus Immune Checkpoint Inhibitor for Patients With Multiple Primary Lung Cancer: A Open, Multi-center, Phase II Clinical Trial (NCT05053802) | Shanghai Pulmonary Hospital, Shanghai, China | 2021-03-21 |